Yale Joins Connecticut Cannabis Company For First State-Approved Study

Describing it as “groundbreaking” research, Yale University School of Medicine announced Friday that it is collaborating with a major cannabis grower to study the effects of medical marijuana on mental health.

Researchers at the school are teaming up with CT Pharmaceutical Solutions Inc., a Connecticut-based producer of medical marijuana products, for a clinical study examining the effectiveness of cannabis on alleviating both stress and pain in patients.

It marks the first study to be approved by the Connecticut Department of Consumer Protection’s Medical Marijuana Research Program that will examine stress and mental health-related issues.

Hartford Business Journal reported that the first phase of the research will “will examine men and women between the ages of 21 to 45 who are recreational marijuana users but do not qualify for medicinal cannabis use,” while phase two “will include men and women ages 21 to 60 with chronic pain.” Every participant in the research will be given a placebo, cannabidiol (CBD), the cannabis compound promoted for health and wellness benefits, or the psychoactive tetrahydrocannabinol (THC), according to the Journal.

The research will also build upon CTPharma’s previous work with Yale professor Rajita Sinha, who in 2017 collaborated with the company on research to

Read More Here…

This entry was posted in Vaporizer E-Cigarette Stocks News. Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback.

Leave a Reply

Your email address will not be published. Required fields are marked *

Your email address will never be published.